0.9922USD+0.53%Mkt Cap: 30.94M USDP/E: —Last update: 2026-05-26
Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap30.94M USD
Enterprise Value—
Revenue (TTM)38.00K USD
Gross Profit-37.55M USD
Net Income (TTM)-61.44M USD
Revenue/Share0.0010 USD
Last Price0.9922 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees39
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.04
PEG—
EV/EBITDA—
EV/Revenue—
P/S806.57
P/B5.44
EPS (TTM)-1.46
EPS (Forward)-0.95
52W Range
0.77007% of range3.884
52W High3.884 USD
52W Low0.7700 USD
Profitability
Gross Margin0.00%
Oper. Margin-71362.50%
EBITDA Margin0.00%
Profit Margin-279263.64%
ROE-1099.27%
ROA-119.94%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-43.44M USD
CapEx (TTM)196.00K USD
FCF Margin—
FCF Yield—
Net Debt—
Net Debt/EBITDA—
Balance Sheet
Debt/Equity5.17
Current Ratio—
Quick Ratio—
Book Value/Sh0.1810 USD
Cash/Share—
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateJul 18, 2024
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)11.25 USD
Target Range6.000 USD – 15.00 USD
# Analysts4
Ownership
Shares Out.31.14M
Float14.58M
Insiders47.59%
Institutions18.50%
Short Interest
Short Ratio3.5d
Short % Float3.84%
Short % Out.2.14%
Shares Short666.77K
Short (prev mo.)736.08K
Technical
SMA 500.9502 (+4.4%)
SMA 2001.321 (-24.9%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)236.31K
Avg Vol (10d)225.83K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—